The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.

Autor: Seervai RNH; Internal Medicine Residency Program, Providence Portland Medical Center, Portland, Oregon, USA.; Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, USA.; Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA., Friske SK; Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA., Chu EY; Department of Dermatology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA., Phillips R; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nelson KC; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Huen A; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Cho WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Aung PP; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Torres-Cabala CA; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Prieto VG; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Curry JL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jazyk: angličtina
Zdroj: Journal of cutaneous pathology [J Cutan Pathol] 2023 Jan; Vol. 50 (1), pp. 72-95. Date of Electronic Publication: 2022 Oct 03.
DOI: 10.1111/cup.14327
Abstrakt: Background: Since their first approval 25 years ago, monoclonal antibodies (mAbs) have become important targeted cancer therapeutics. However, dermatologic toxicities associated with non-immune checkpoint inhibitor (non-ICI) mAbs may complicate the course of cancer treatment. Data on the incidence and types of these reactions are limited.
Methods: A comprehensive review was conducted on dermatologic toxicities associated with different classes of non-ICI mAbs approved for treatment of solid tumors and hematologic malignancies. The review included prospective Phase 1, 2, and 3 clinical trials; retrospective literature reviews; systematic reviews/meta-analyses; and case series/reports.
Results: Dermatologic toxicities were associated with several types of non-ICI mAbs. Inflammatory reactions were the most common dermatologic toxicities, manifesting as maculopapular, urticarial, papulopustular/acneiform, and lichenoid/interface cutaneous adverse events (cAEs) with non-ICI mAbs. Immunobullous reactions were rare and a subset of non-ICI mAbs were associated with the development of vitiligo cAEs.
Conclusion: Dermatologic toxicities of non-ICI mAbs are diverse and mostly limited to inflammatory reactions. Awareness of the spectrum of the histopathologic patterns of cAE from non-ICI mAbs therapy is critical in the era of oncodermatology and oncodermatopathology.
(© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje